摘要
阿尔茨海默病(AD)的特征在于淀粉样蛋白- β (Aβ )肽有害堆积形成老年斑,过度磷酸化tau蛋白形成神经原纤维缠结,以及大脑皮质中胆碱能突触损失。Aβ负载的斑块沉积导致小胶质细胞活化随后产生活性氧 (ROS),包括自由基。衰老的和AD神经元特别易受ROS和其他有毒刺激的侵袭。因此,减少对抗ROS的神经元的脆弱性的药物可能对AD的治疗或预防提供治疗价值。在本研究中,我们的目的是测试静脉内免疫球蛋白( IVIG)治疗是否可以在氧化损伤中维持和保护神经元。我们报道了该IVIG 治疗在原代大鼠海马神经元中保护神经元活性和突触蛋白,此外,我们证明了IVIG 疗法在原代人胎和脑混合培养物中的耐受性。事实上,高剂量(20mg/ml)的IVIG治疗能被原代人脑培养物耐受良好并表现出正常的神经细胞的表型。我们还观察到,IVIG对抗ROS介导的氧化损伤在原代人胎和脑混合培养物上有强大的神经维持作用,这些结果表明,静脉注射免疫球蛋白疗法有巨大的潜力来维持和保护原代人类神经元富集培养物且潜在地拯救受氧化损伤濒死的神经元。因此,我们的研究表明IVIG 疗法对于设计用于防止和延缓神经变性的发病以及AD病理的临床试验可能是一个重要的治疗药物。
关键词: 老化,脑,海马神经元,人类神经元,免疫球蛋白,神经保护,神经维持,神经救援,氧化应激,突触,突触蛋白
Current Alzheimer Research
Title:Intravenous Immunoglobulin Treatment Preserves and Protects Primary Rat Hippocampal Neurons and Primary Human Brain Cultures Against Oxidative Insults
Volume: 11 Issue: 7
Author(s): Debomoy K. Lahiri and Balmiki Ray
Affiliation:
关键词: 老化,脑,海马神经元,人类神经元,免疫球蛋白,神经保护,神经维持,神经救援,氧化应激,突触,突触蛋白
摘要: Alzheimer’s disease (AD) is characterized by deleterious accumulation of amyloid-β (Aβ) peptide into senile plaque, neurofibrillary tangles formed from hyperphosphorylated tau protein, and loss of cholinergic synapses in the cerebral cortex. The deposition of Aβ-loaded plaques results in microglial activation and subsequent production of reactive oxygen species (ROS), including free radicals. Neurons in aging and AD brains are particularly vulnerable to ROS and other toxic stimuli. Therefore, agents that decrease the vulnerability of neurons against ROS may provide therapeutic values for the treatment or prevention of AD. In the present study, our goal was to test whether intravenous immunoglobulin (IVIG) treatment could preserve as well as protect neurons from oxidative damage. We report that treatment with IVIG protects neuronal viability and synaptic proteins in primary rat hippocampal neurons. Further, we demonstrate the tolerability of IVIG treatment in the primary human fetal mixed brain cultures. Indeed, a high dose (20mg/ml) of IVIG treatment was well-tolerated by primary human brain cultures that exhibit a normal neuronal phenotype. We also observed a potent neuropreservatory effect of IVIG against ROS-mediated oxidative insults in these human fetal brain cultures. These results indicate that IVIG treatment has great potential to preserve and protect primary human neuronal-enriched cultures and to potentially rescue dying neurons from oxidative insults. Therefore, our findings suggest that IVIG treatment may represent an important therapeutic agent for clinical trials designed to prevent and delay the onset of neurodegeneration as well as AD pathology.
Export Options
About this article
Cite this article as:
Lahiri K. Debomoy and Ray Balmiki, Intravenous Immunoglobulin Treatment Preserves and Protects Primary Rat Hippocampal Neurons and Primary Human Brain Cultures Against Oxidative Insults, Current Alzheimer Research 2014; 11 (7) . https://dx.doi.org/10.2174/1567205011666140812113851
DOI https://dx.doi.org/10.2174/1567205011666140812113851 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Proteinaceous Inhibitors of Serine Proteases
Current Pharmaceutical Design Targeting Neuronal Nicotinic Receptors: a Path to New Therapies
Current Drug Targets - CNS & Neurological Disorders Health Outcomes Associated with Hormone Therapy in Australian Women
Current Drug Safety The Emerging Role of MicroRNA in Schizophrenia
CNS & Neurological Disorders - Drug Targets Alzheimers Disease and Oxidative Stress: The Old Problem Remains Unsolved
Current Medicinal Chemistry - Central Nervous System Agents Lack of Association between Genetic Polymorphism of Circadian Genes (PER2, PER3, CLOCK and OX2R) with Late Onset Depression and Alzheimer's Disease in a Sample of a Brazilian Population (Circadian Genes, Late-Onset Depression and Alzheimer's Disease)
Current Alzheimer Research Neonatal Atlas Templates for the Study of Brain Development Using Magnetic Resonance Images
Current Medical Imaging Tackling the Elusive Challenges Relevant to Conquering the 100-Plus Year Old Problem of Alzheimer’s Disease
Current Alzheimer Research Stroke Suggests Increased Risk of Dementia
Current Alzheimer Research Natural Products and their (Semi-)Synthetic Forms in the Treatment of Migraine: History and Current Status
Current Medicinal Chemistry Structural Exploration of Synthetic Chromones as Selective MAO-B Inhibitors: A Mini Review
Combinatorial Chemistry & High Throughput Screening Analytical Tools for the Determination of Antioxidants and Antioxidant Capacity in Biological Samples, Principles and Applications
Current Organic Chemistry Applicability and Approaches of (Meth) Acrylate Copolymers (Eudragits) in Novel Drug Delivery Systems
Current Drug Therapy Mitochondrial Triglyceride Transfer Protein Inhibition: New Achievements in the Treatment of Dyslipidemias
Current Pharmaceutical Design Myogenic Tone as a Therapeutic Target for Ischemic Stroke
Current Vascular Pharmacology Pharmacological Approaches to Chronic Spinal Cord Injury
Current Pharmaceutical Design Are Retinoids a Promise for Alzheimer’s Disease Management?
Current Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers Quality Control Optimization Solutions for Determination of Rutin in Supplements Containing Ginkgo Biloba Extract
Current Pharmaceutical Analysis Immune Functions of Glia and Neurons in the Central Nervous System
Current Immunology Reviews (Discontinued)